- Home
- ICON vs CHRO Comparison
ICON vs CHRO Comparison
Compare ICON & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- CHRO
- Stock Information
- Founded
- ICON 2023
- CHRO 2002
- Country
- ICON Greece
- CHRO United States
- Employees
- ICON N/A
- CHRO N/A
- Industry
- ICON
- CHRO
- Sector
- ICON
- CHRO
- Exchange
- ICON Nasdaq
- CHRO Nasdaq
- Market Cap
- ICON 3.4M
- CHRO 3.9M
- IPO Year
- ICON 2024
- CHRO 2024
- Fundamental
- Price
- ICON $2.78
- CHRO $0.62
- Analyst Decision
- ICON Strong Buy
- CHRO Strong Buy
- Analyst Count
- ICON 1
- CHRO 1
- Target Price
- ICON $7.00
- CHRO N/A
- AVG Volume (30 Days)
- ICON 33.5K
- CHRO 53.7K
- Earning Date
- ICON 12-03-2024
- CHRO 11-13-2024
- Dividend Yield
- ICON 2.88%
- CHRO N/A
- EPS Growth
- ICON N/A
- CHRO N/A
- EPS
- ICON 0.35
- CHRO N/A
- Revenue
- ICON $4,810,000.00
- CHRO N/A
- Revenue This Year
- ICON $64.08
- CHRO N/A
- Revenue Next Year
- ICON $100.00
- CHRO N/A
- P/E Ratio
- ICON $8.01
- CHRO N/A
- Revenue Growth
- ICON 5.71
- CHRO N/A
- 52 Week Low
- ICON $1.81
- CHRO $0.45
- 52 Week High
- ICON $3.85
- CHRO $6.00
- Technical
- Relative Strength Index (RSI)
- ICON N/A
- CHRO 46.49
- Support Level
- ICON N/A
- CHRO $0.51
- Resistance Level
- ICON N/A
- CHRO $0.67
- Average True Range (ATR)
- ICON 0.00
- CHRO 0.07
- MACD
- ICON 0.00
- CHRO 0.00
- Stochastic Oscillator
- ICON 0.00
- CHRO 70.83
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a Growth-oriented company that operates as a holding company for the purpose of acquiring, owning, chartering and operating dry bulk vessels through its subsidiaries. The company generates its revenues by chartering the Initial Vessels to regional and international dry bulk operators, commodity traders and end users.
About CHRO Chromocell Therapeutics Corporation
Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.